Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.
- NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_assertion description "[Low-dose demethylating agents such as 5-aza-2'-deoxycytidine (decitabine, DAC) and 5-azacytidine (azacitidine, Vidaza) have been explored for the treatment of myelodysplasia, acute myeloid leukemia, and hemoglobinopathies since the early 1980s, aiming to revert a methylator phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.
- NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_assertion evidence source_evidence_literature NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.
- NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_assertion SIO_000772 16292549 NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.
- NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_assertion wasDerivedFrom befree-2016 NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.
- NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_assertion wasGeneratedBy ECO_0000203 NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.
- befree-2016 importedOn "2016-02-19" NP523035.RAg84psC3AQD6Cbml8nI-JNT8B5WvigQlDQ2snyiyJKJ8130_provenance.